COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Follow-Up Questions
COSCIENS Biopharma Inc의 CEO는 누구입니까?
Mr. Gilles Gagnon은 2000부터 회사에 합류한 COSCIENS Biopharma Inc의 President입니다.
CSCI 주식의 가격 성능은 어떻습니까?
CSCI의 현재 가격은 $2.7이며, 전 거래일에 decreased 0% 하였습니다.
COSCIENS Biopharma Inc의 주요 사업 주제나 업종은 무엇입니까?
COSCIENS Biopharma Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
